72 related articles for article (PubMed ID: 17670899)
1. Differential effects of dialysis and ultrafiltrate from individuals with CKD, with or without diabetes, on platelet phosphatidylserine externalization.
Wang Y; Beck W; Deppisch R; Marshall SM; Hoenich NA; Thompson MG
Am J Physiol Renal Physiol; 2008 Jan; 294(1):F220-8. PubMed ID: 17670899
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors.
Wang Y; Beck W; Deppisch R; Marshall SM; Hoenich NA; Thompson MG
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C328-36. PubMed ID: 17625040
[TBL] [Abstract][Full Text] [Related]
3. Intradialytic and postdialytic platelet activation, increased platelet phosphatidylserine exposure and ultrastructural changes in platelets in children with chronic uremia.
Elshamaa MF; Elghoroury EA; Helmy A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):230-9. PubMed ID: 19521197
[TBL] [Abstract][Full Text] [Related]
4. L-carnitine inhibits a subset of platelet activation responses in chronic uraemia.
Bonomini M; Sirolli V; Dottori S; Amoroso L; Di Liberato L; Arduini A
Nephrol Dial Transplant; 2007 Sep; 22(9):2623-9. PubMed ID: 17478491
[TBL] [Abstract][Full Text] [Related]
5. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
Sjöberg B; Anderstam B; Suliman M; Alvestrand A
Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
[TBL] [Abstract][Full Text] [Related]
6. Serotonin levels in platelet-poor plasma and whole blood in people with type 2 diabetes with chronic kidney disease.
Hara K; Hirowatari Y; Shimura Y; Takahashi H
Diabetes Res Clin Pract; 2011 Nov; 94(2):167-71. PubMed ID: 21775011
[TBL] [Abstract][Full Text] [Related]
7. Serotonin metabolism in patients undergoing hemodialysis.
Kanai H; Ishii Y; Maezawa A; Yano S; Naruse T
Clin Nephrol; 1996 Apr; 45(4):244-9. PubMed ID: 8861800
[TBL] [Abstract][Full Text] [Related]
8. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.
Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A
J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369
[TBL] [Abstract][Full Text] [Related]
9. Skin blood flow in patients with stage 5 chronic kidney disease on hemodialysis.
Ngo B; Rongey C; Hiscox B; Rendell M; Woodley D; Smogorzewski M
J Ren Nutr; 2010 Sep; 20(5 Suppl):S89-94. PubMed ID: 20797579
[TBL] [Abstract][Full Text] [Related]
10. Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.
Serebruany VL; El Mouelhi M; Pfannkuche HJ; Rose K; Marro M; Angiolillo DJ
Am J Ther; 2010; 17(6):543-52. PubMed ID: 19797939
[TBL] [Abstract][Full Text] [Related]
11. Phosphatidylserine exposure and other apoptotic-like events in Bernard-Soulier syndrome platelets.
Rand ML; Wang H; Bang KW; Teitel JM; Blanchette VS; Freedman J; Nurden AT
Am J Hematol; 2010 Aug; 85(8):584-92. PubMed ID: 20658588
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
14. The role of erythrocytes phosphatidylserine exposure in anemia in peritoneal dialysis patients.
Bi SH; Cheng LT; Wang T
Ren Fail; 2006; 28(7):573-6. PubMed ID: 17050240
[TBL] [Abstract][Full Text] [Related]
15. Implementing KDOQI CKD definition and staging guidelines in Southern California Kaiser Permanente.
Rutkowski M; Mann W; Derose S; Selevan D; Pascual N; Diesto J; Crooks P
Am J Kidney Dis; 2009 Mar; 53(3 Suppl 3):S86-99. PubMed ID: 19231766
[TBL] [Abstract][Full Text] [Related]
16. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia.
Bonomini M; Dottori S; Amoroso L; Arduini A; Sirolli V
J Thromb Haemost; 2004 Aug; 2(8):1275-81. PubMed ID: 15304031
[TBL] [Abstract][Full Text] [Related]
17. Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone.
Randriamboavonjy V; Pistrosch F; Bölck B; Schwinger RH; Dixit M; Badenhoop K; Cohen RA; Busse R; Fleming I
Circulation; 2008 Jan; 117(1):52-60. PubMed ID: 18071073
[TBL] [Abstract][Full Text] [Related]
18. Effect of pravastatin in people with diabetes and chronic kidney disease.
Tonelli M; Keech A; Shepherd J; Sacks F; Tonkin A; Packard C; Pfeffer M; Simes J; Isles C; Furberg C; West M; Craven T; Curhan G
J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
[TBL] [Abstract][Full Text] [Related]
19. [On-line HFR and removal of uremic toxins inducing the loss of phospholipidic asymmetry of the erythrocyte membrane].
Sirolli V; Cappelli P; Amoroso L; Di Liberato L; Muscianese P; Santarelli P; Del Rosso G; Bonomini M
G Ital Nefrol; 2004; 21 Suppl 30():S208-11. PubMed ID: 15750987
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.
Koga H; Sugiyama S; Kugiyama K; Fukushima H; Watanabe K; Sakamoto T; Yoshimura M; Jinnouchi H; Ogawa H
Eur Heart J; 2006 Apr; 27(7):817-23. PubMed ID: 16434416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
